Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types.
In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-nflammatory and anti-fibrotic. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. MSCs appear to be an exceptionally promising tool for cell therapy, because of their unusual advantages, which include availability, expand ability, transplant ability, and ethical implications.
Interest in therapeutic applications of human MSCs arises from their diverse ability to differentiate into a range of cell types, as well as their ability to migrate to sites of tissue injury/inflammation or tumor growth. Additionally, MSCs well-suited for use in the exponential growth area of 3D printing, because of their capacity to form structural tissues.
Growing attention is now being given to manufacturing technologies to support commercial-scale production of MSCs. Numerous market competitors are also exploring commercialization strategies for MSC-derived exosomes, because exosomes represent a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.
As the most common stem cell type being used in regenerative medicine, there is substantial potential for growth within the MSC market. Today, there are more than 40,000 scientific publications published about the cell type , more than 800 clinical trials underway worldwide , and Google Trend data reveals that MSC searches are more than twice as common as the next most common adult stem cell type .
The Burgeoning Market for Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are the most utilized cell type within the regenerative medicine industry. To support this rapidly expanding marketplace, this 200+ page global strategic report presents trend rate data for MSC market, including rates of MSC patents, grants, scientific publications, and clinical trials, as well associal analytics that identify online behavior related to MSCs.
The report describes the current status of mesenchymal stem cell (MSC) research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and uses of MSCs in cell therapy. It explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 73 leading competitors within the MSC marketplace.
Because MSC therapy is an integrated component of Advanced Therapy Medicinal Products (ATMPs), this market report also provides an introduction to ATMPs.
For pharmaceutical companies, the report reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies. With “Big Pharma” diversifying their product development pipelines by investing in cell therapy companies, MSC companies now represent promising candidates for collaboration, investment, and acquisition.
Based in Washington, DC, Bio Informant is first and only market research firm to specialize in the stem cell industry. Unlike other publishers that hire analysts from foreign countries, Bio Informant is an American-based company with more than a decade of experience with tracking the stem cell market (2006 to present). Bio Informant compiled this global strategic report using interviews with more than 90 individuals from across the stem cell industry.
Bio Informant conducted interviews with representatives from Cynata Therapeutics (first company to bring a iPSC-derived MSC therapeutic product into a clinical trial), Rooster Bio (global leader in MSC manufacturing technology that can produce to tens of billions of cells in suspension bioreactors), Pluristem Therapeutics (commercializing placenta-derived mesenchymal-like adherent stromal cells in late-stage clinical trials), Bio Eden (leading company preserving MSCs derived from dental tissues), Regenexx (world’s leading provider of MSC therapies for orthopedic applications), and many more.
The report also incorporates secondary findings from SEC filings, company websites, press releases, investor presentations, government policy documents, Google Trends, and Google Adwords.
Claim this report to:
Identify the market segments that compose the MSC industry
Reveal the key market players competing in each market niche
Identify opportunities for MSC product development
Access market size determinations for the MSC market, with projections through 2022
Exploit emerging opportunities within the MSC marketplace
Table of Contents
1. Report Overview 14 1.1 Statement of the Report 14 1.2 Executive Summary 16
2. Introduction 18
3. Advanced Therapy Medicinal Products (ATMPs) 20 3.1 Major Therapeutic Areas of Interests in ATMPs Sector 20 3.2 Price of Market-Stage ATMPs 21 3.3 FDA-Approved ATMPs 21 3.4 EC-Approved ATMPs 22
4. Stem Cells: A Brief Overview 24 4.1 Embryonic Stem Cells (ESCs) 24 4.2 Induced Pluripotent Stem Cells (iPSCs) 25 4.3 Types of Specialized Cells Derived from Stem Cells 26 4.4 Types of Stem Cells in Human Body 27 4.4.1 Human Embryonic Stem Cells (hESCs) 27 4.4.2 Embryonic Germ Cells (EG-Cells) 27 4.4.3 Fetal Stem Cells 28 4.4.4 Umbilical Cord Stem Cells 28 4.5 Adult Stem Cells 29 4.5.1 Hematopoietic Stem Cells (HSCs) 29 4.5.2 Mesenchymal Stem Cells (MSCs) 30 4.5.3 Neural Stem Cells (NSCs) 30 4.6 Characteristics of Different Types of Stem Cells 31 4.7 Applications of Stem Cells in Medicine 31
5. Mesenchymal Stem Cells (MSCs): A Detailed Overview 33 5.1 A New Name for MSCs 33 5.1.1 History and Timeline of MSCs Nomenclature 34 5.2 Functions of MSCs 35 5.3 Sources of MSCs 36 5.4 Isolation and Culturing of hMSCs 37 5.4.1 Cell Surface Markers in MSCs 38 5.4.2 In Vitro Differentiation Potential of MSCs 39 5.5 Key Features of Different Types of MSCs 40 5.6 Chronic Diseases Treatable by hMSCs 42 5.7 Common Diseases Registered for MSC-Based Cell Therapy 43 5.8 Advantages of MSCs in Cell Therapy 45 5.9 Comparison of MSCs with Other Stem Cell Types 46 5.10 Drawbacks of Autologous MSCs and Advantages of Allogeneic MSCs 46 5.10.1 Application Strategies for Allogeneic MSCs 47 5.11 Mechanism of Action of MSCs in Treating Diseases 48 5.12 Tissue Regeneration 49 5.13 Immune Modulation 49 5.14 Manufacture of MSCs 51 5.14.1 Safety and Potency Assays 51 5.14.2 Surface Markers of MSC 52 5.14.3 BM-MNC Isolation and Plating 53 5.14.4 Passaging and Harvesting 53 5.14.5 Cryopreservation of MSCs 54 5.14.6 Donor Eligibility and Cell Collection 55 5.14.7 Regulatory Framework of MSC Therapies 55 5.14.8 Contract Development and Manufacturing Organizations (CDMO) 56
6.1 MSCs for GvHD 57 6.2 MSCs for Cardiovascular Repair 58 6.3 MSCs for Liver Disease 58 6.4 MSC for Bone/Cartilage Disease 59 6.5 Approved MSC-Based Products 60 6.5.1 Cartistem 60 6.5.2 Stempeucel 60 6.5.3 Mesenchymal Precursor Cells (MPCs) from Mesoblast 61 6.5.4 Cupistem 62 6.5.5 Prochymal 62 6.5.6 AlloStem 62 6.5.7 Cellgram-AMI 63 6.5.8 Osteocel Plus 63 6.5.9 Trinity Evolution 64 6.5.10 CardioRel 64 6.5.11 Temcell 64 6.6 Bone Matrices Containing MSCs 65 6.6.1 Cost of Bone Matrices Containing MSCs 65 6.6.2 Tissue Engineered Orthopedic Product Candidates Containing MSCs 66 6.7 Pricing of Approved Cell Therapy Products 67
7. Stem Cell Research Publications, Funding And Patents 69 7.1 Volume of Scientific Papers Published on MSCs 71 7.1.1 Number of Publications on MSCs by Major Applications 72 7.2 Stem Cell Research around the World 72 7.3 NIH Funding for MSCs Research 73 7.4 Stem Cell Patents Landscape 78
8. Clinical Trials Involving MSCS: An Overview 80 8.1 Current Clinical Trial Scenario 80 8.2 Geographical Share of MSC Clinical Trials 81 8.2.1 Number of Clinical Trials using MSCs by Geography/Country 82 8.3 Sources of MSCs for Current Clinical Trials 82 8.4 Diseases Addressed by MSCs in the Ongoing Clinical Trials 83 8.5 Active Clinical Trials using MSCs 84 8.6 MSC Clinical Trial Outcomes, 2011-2016 85 8.7 Selected Clinical Trials Sponsored by Universities 86 8.7.1 Celal Bayar University (NCT02824393) 87 8.7.2 University of Jordan (NCT02118519) 87 8.7.3 Ankara University (NCT03106662) 87 8.7.4 University Hospital of Liege (NCT00504803) 87 8.7.5 Acibadem University (NCT02285673) 88 8.7.6 University of Sao Paulo (NCT01297972) 88 8.7.7 Cairo University (NCT02387749) 88 8.8 Selected Clinical Trials Sponsored by Cell Therapy Companies 89 8.8.1 Scinow Biotechnology Co., Ltd. (NCT03184935) 89 8.8.2 Mesoblast Ltd. (NCT00294112) 90 8.8.3 Cellular Biomedicine Group Ltd. (NCT01809769) 90 8.8.4 Alliancells Bioscience Corporation Ltd. (NCT01573923) 90 8.8.5 Pharmicell Co., Ltd. (NCT01676441) 90 8.8.6 Shenzhen Hometcorn Biotechnology Co., Ltd. 91 8.8.7 Sclnow Biotechnology Co., Ltd. (NCT03180450) 91 8.9 Clinical Trials using MSCs for Cardiovascular Diseases 92 8.9.1 Corporate Investment in Cardiovascular Diseases using MSC Therapy 93 22.214.171.124 MPC-150-IM from Mesoblast 94 126.96.36.199 CLBS10 from Caladrius 95 188.8.131.52 C-Cure from Celyad 95 184.108.40.206 Ixmyelocel-T from Vericel 95 220.127.116.11 MultiStem from Athersys 96 8.10 MSCs for Osteoarthritis 96 8.11 MSCs in Wound Healing 98 8.12 MSCs for Liver Diseases 99 8.13 MSCs for Lung Disorders 100 8.14 Clinical Trials using MSCs for Eye Disorders 101 8.15 MSCs for Kidney Disorders 102 8.16 MSCs for Diabetes 103 8.17 MSCs for Graft vs. Host Disease (GvHD) 104 8.18 MSCs for Inflammatory Bowel Diseases 105 8.19 MSCs for Multiple Sclerosis 106 8.20 Status of MSC Clinical Research in Specific Diseases 106 8.20.1 Graft v. Host Disease (GvHD) 106 8.20.2 OA & RA 107 8.20.3 Inflammatory Airway and Pulmonary Diseases 107 8.20.4 Multiple Sclerosis (MS) 107 8.20.5 Inflammatory Bowel Disease (IBD) 108 8.20.6 Genetically Engineered MSCs 108
9. Partnering Activities In Cell Therapy Sector 110 9.1 Collaboration between Lonza and Nikon 111 9.2 Hitachi’s Purchase of PCT from Caladrius Biosciences 111 9.3 Collaboration between Regeneus Ltd. and Asahi Glass. Co. on Progenza 112 9.4 Collaboration between RepliCel Life Sciences and Shiseido Co., Ltd. 112 9.5 Collaboration between SanBio Life Sciences and Sumitomo 112 9.6 Partnership and License Agreement between Healios K.K. and Athersys Inc. 113 9.7 Cell Therapy Ltd.’s License to Daiichi Sankyo 113 9.8 TiGenix’s License to Takeda Pharmaceuticals 114 9.9 Celyad’s License to Ono Pharmaceuticals 114 9.10 Collaboration Kolon Life Sciences and Mitsubishi Tanabe 114 9.11 Collaboration between Steminent Biotherapeutics and ReproCELL Inc. 115 9.12 Kite Pharma’s Partnership with Daiichi Sankyo 115 9.13 Acquisition of Cellular Dynamics by Fujifilm Holdings 115 9.14 License Agreement between Cynata Therapeutics and Fujifilm 116 9.15 Gilead to Acquire Kite Pharma 116 9.16 Big Pharma’s Strategy in Advanced Therapy Sector 116 9.16.1 Collaboration between Sangamo and Pfizer 117 9.16.2 Acquisition of 3D Printing Systems from Tissue Regeneration Systems by DePuy Synthes Products (J&J) 118 9.16.3 New JLABS Opened by J&J 118 9.16.4 Collaboration between GSK and Miltenyl Biotec 118 9.17 Big Pharma’s Interest in Cell Therapy 119 9.17.1 GlaxoSmithKline (GSK) 119 9.17.2 Pfizer 120 9.17.3 Novartis 120 9.17.4 AstraZeneca 120 9.17.5 Roche 121 9.17.6 Johnson & Johnson 121 9.17.7 Sanofi 121 9.18 Big Pharma Strategy in Advanced Therapies 122 9.18.1 Value of Big Pharma Deals in Cell and Gene Therapy 123 9.19 Recent Events in Advanced Therapies Sector 124 9.20 Geographical Distribution of Cell Therapy Companies 125
Figure 3.1: Major Indications of Advanced Therapy Clinical Trials 18 Figure 4.1: Differentiation of Stem Cells into Adult Specialized Cells 21 Figure 4.2: Differentiation of Embryonic Stem Cells into Adult Specialized Cells 22 Figure 4.3: Differentiation of Induced Pluripotent Stem Cells into Adult Specialized Cells 23 Figure 4.4: Types of Specialized Cells Derived from Stem Cells 23 Figure 4.5: Applications of Stem Cells 29 Figure 5.1: Types of Common Diseases Registered for MSC-Based Cell Therapy 41 Figure 5.2: Some Mechanisms of MSCs in Therapeutic Application 45 Figure 5.3: Steps in the Manufacturing Process of MSCs 48 Figure 6.1: Clinical Trials of MSCs Classified by Disease Type 54 Figure 7.1: Stem Cell Research Publications Landscape 66 Figure 7.2: Number of Published Scientific Papers on MSCs 68 Figure 7.3: Number of Publications on MSCs by Major Applications, 2016 69 Figure 8.1: Currently Active Clinical Trials using MSCs 78 Figure 8.2: MSC-Based Clinical Trials by Geography 78 Figure 8.3: Sources of MSCs used in Current Clinical Trials 80 Figure 8.4: Diseases Addressed by MSCs in the Ongoing Clinical Trials 80 Figure 9.1: Value of Deals Undertaken by Big Pharma in Gene and Cell Therapy Sector, 2016 120 Figure 9.2: Geographical Distribution of Cell Therapy Companies 123 Figure 10.1: Global Market for Mesenchymal Stem Cells and Products, 2016-2022 129
Write comment about above report:
Published By: BioInformant Worldwide, L.L.C.
BioInformant Worldwide, L.L.C.1004
Did you find what you are/were looking for
If not, read below and browse through other relevant pages for similar market research
reports OR get in touch with us through the form/contact info in your right navigation
panel and well share relevant market report titles for you to explore.
We are on:
500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.